The Kenya Medical Research Institute is ready to begin Covid-19 vaccine trials. Kemri director general Kombe Yeri said the ChAdOx1 nCoV-19 vaccine trials will begin with a smaller number of volunteers. Professor George Warimwe, a researcher at Kemri said the ChAdOx1 nCoV-19 vaccine is at phase 3 of development. Warimwe said some of the 40 volunteers will receive the ChAdOx1 nCoV-19 vaccine while the other group will receive rabies vaccine. We know the rabies vaccine does not protect against Covid-19 but will give participants protection against rabies as a benefit for taking part in the trials,” Warimwe said.

Source: The Star September 18, 2020 14:48 UTC